title: Angiosarcoma in children - still uncontrollable oncological problem. The report of the Polish Paediatric Rare Tumours Study.
abstract: Angiosarcoma in children - still uncontrollable oncological problem. The report of the Polish Paediatric Rare Tumours StudyAngiosarcoma is a rare, highly malignant vascular neoplasm with little data available on its clinical course and management in children. Ten children with angiosarcoma (M/F: 6/4; aged 2, 3-16 years) registered in Polish Paediatric Rare Tumours and Soft Tissue Sarcomas Studies between 1992 and 2006. Primary tumour exceeded 5 cm in seven patients and affected mainly deep tissues (heart-2, head/neck, bladder, brain, liver and upper limb - one patient each). Four patients had regional and two metastatic diseases (lungs and bones). Three patients were initially misdiagnosed as haemangioma. Complete primary excision was unfeasible even in local stages. All patients received supplementing chemotherapy with no response in four. Radiotherapy was given to five children, including three after relapse. Three of five secondary tumour resections proved complete. Seven patients experienced relapses (mainly metastatic) and two continuous progression. Relapsed patients received chemotherapy +/- radiotherapy and surgery (three). Nine patients died of disease (overall survival 6-66 months), and one child after mutilating secondary resection is alive. Angiosarcoma in children is highly aggressive with an extremely poor prognosis. Complete primary excision is unfeasible, even in seemingly local stages. The response to chemotherapy is poor and the large number of metastatic recurrences suggests a need for systemic therapy modifications.
authors.affiliation: Department of Paediatrics, Haematology, Oncology and Endocrinology, Medical University of Gdansk, Gdansk. ebien@amg.gda.pl
authors.forename: E
authors.initials: E
authors.lastname: Bien
authors.forename: T
authors.initials: T
authors.lastname: Stachowicz-Stencel
authors.forename: A
authors.initials: A
authors.lastname: Balcerska
authors.forename: J
authors.initials: J
authors.lastname: Godzinski
authors.forename: B
authors.initials: B
authors.lastname: Kazanowska
authors.forename: M
authors.initials: M
authors.lastname: Perek-Polnik
authors.forename: W
authors.initials: W
authors.lastname: Madziara
authors.forename: A
authors.initials: A
authors.lastname: Rybczynska
authors.forename: A
authors.initials: A
authors.lastname: Kurylak
authors.forename: B
authors.initials: B
authors.lastname: Zalewska-Szewczyk
authors.forename: J
authors.initials: J
authors.lastname: Peregud-Pogorzelski
mesh_terms: D000293:Adolescent; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D018450:Disease Progression; D006394:Hemangiosarcoma / Q000401:mortality / Q000473:pathology* / Q000628:therapy*; D006801:Humans; D008297:Male; D011044:Poland / Q000453:epidemiology; D011379:Prognosis; D011878:Radiotherapy; D012008:Recurrence; D012189:Retrospective Studies; D012509:Sarcoma / Q000401:mortality / Q000473:pathology* / Q000628:therapy*; D015996:Survival Rate
chemical_list: D000970:Antineoplastic Agents